Synthetic Biologics Inc (NYSEMKT:SYN) Given Average Recommendation of “Buy” by Brokerages
Shares of Synthetic Biologics Inc (NYSEMKT:SYN) have been given an average rating of “Buy” by the eight brokerages that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $4.46.
SYN has been the topic of several analyst reports. ValuEngine lowered shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, June 2nd. William Blair restated an “outperform” rating and set a $5.00 price target on shares of Synthetic Biologics in a research report on Monday, May 22nd. Finally, Zacks Investment Research raised shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $0.50 price objective on the stock in a report on Wednesday, May 10th.
Shares of Synthetic Biologics (NYSEMKT SYN) traded down 3.6505% on Monday, hitting $0.5094. 1,188,133 shares of the stock traded hands. The stock has a 50 day moving average of $0.61 and a 200 day moving average of $0.70. The company’s market cap is $62.09 million. Synthetic Biologics has a one year low of $0.41 and a one year high of $1.94.
Synthetic Biologics (NYSEMKT:SYN) last released its quarterly earnings data on Thursday, May 4th. The company reported ($0.02) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.07) by $0.05. Equities analysts anticipate that Synthetic Biologics will post ($0.25) earnings per share for the current year.
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Norges Bank acquired a new stake in Synthetic Biologics during the fourth quarter valued at approximately $356,000. Bank of New York Mellon Corp increased its stake in Synthetic Biologics by 3.1% in the first quarter. Bank of New York Mellon Corp now owns 263,598 shares of the company’s stock valued at $166,000 after buying an additional 7,962 shares during the period. Finally, UBS Group AG increased its stake in Synthetic Biologics by 10.3% in the first quarter. UBS Group AG now owns 214,357 shares of the company’s stock valued at $135,000 after buying an additional 20,038 shares during the period.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.